Table 2 Patient characteristics by tumor subtype

Sex

Male

28 (53.8)

39 (50.0)

31 (51.7)

98 (51.6)

p = 0.9116

Female

24 (46.2)

39 (50.0)

29 (48.3)

92 (48.4)

Age

< 70

37 (71.2)

65 (83.3)

44 (73.3)

146 (76.8)

p = 0.2011

≥70

15 (28.8)

13 (16.7)

16 (26.7)

44 (23.2)

CEA

<ULN

33 (63.5)

51 (65.4)

29 (48.3)

113 (59.5)

p = 0.1847

≥ULN

14 (26.9)

17 (21.8)

20 (33.3)

51 (26.8)

Unknown

5 (9.6)

10 (12.8)

11 (18.3)

26 (13.7)

Tumor location

Right side

26 (50.0)

18 (23.1)

20 (33.3)

64 (33.7)

p = 0.0063

Left side

26 (50.0)

60 (76.9)

40 (66.7)

126 (66.3)

T stage

T1-T3

30 (57.7)

50 (64.1)

32 (53.3)

112 (58.9)

p = 0.4335

T4

22 (42.3)

28 (35.9)

28 (46.7)

78 (41.1)

Histology

Non muc

46 (88.5)

78 (100.0)

58 (96.7)

182 (95.8)

p = 0.0036

muc

6 (11.5)

0 (0.0)

2 (3.3)

8 (4.2)

Tumor grade

por & muc

11 (21.2)

2 (2.6)

4 (6.7)

17 (8.9)

p = 0.0010

tub

41 (78.8)

76 (97.4)

56 (93.3)

173 (91.1)

Lymphatic invasion

Negative

14 (26.9)

28 (35.9)

13 (21.7)

55 (28.9)

p = 0.1754

Positive

38 (73.1)

50 (64.1)

47 (78.3)

135 (71.1)

Vascular invasion

Negative

14 (26.9)

26 (33.3)

11 (18.3)

51 (26.8)

p = 0.1433

Positive

38 (73.1)

52 (66.7)

49 (89.7)

139 (73.2)

N stage

N1

13 (25.0)

39 (50.0)

23 (38.3)

75 (39.5)

p = 0.0021

N2

34 (65.4)

39 (50.0)

31 (51.7)

104 (54.7)

N3

5 (9.6)

0 (0.0)

6 (10.0)

11 (5.8)

Number of resected lymph nodes

< 12

3 (5.8)

11 (14.1)

6 (10.0)

20 (10.5)

p = 0.3125

≥12

49 (94.2)

67 (85.9)

54 (90.0)

170 (89.5)

Adjuvant chemotherapy

With oxaliplatin

25 (48.1)

42 (53.8)

28 (46.7)

95 (50.0)

p = 0.6686

Without oxaliplatin

27 (51.9)

36 (46.2)

32 (53.3)

95 (50.0)